New XOFIGO® (radium-223 dichloride) Data in Metastatic Castration-Resistant Prostate Cancer from Phase III PEACE III Trial Published in Annals of Oncology

Posted on 06/09/2025

Annals of Oncology published full results from the pivotal investigational Phase III PEACE III trial, evaluating XOFIGO® (radium-223 dichloride) in combination with enzalutamide, an AR pathway inhibitor (ARPI), versus enzalutamide alone in the first-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.

View Resource

Cancer of unknown primary (CUP): Implementation of a robust pathway

Posted on 05/27/2025

There is a need to improve upon the diagnostic strategies for cancer of unknown primary ​(CUP) tumors​. And reducing delays in diagnosis and identifying patients at earlier stages may potentially ​improve patient outcomes. These guides aim to highlight key considerations to take into account when establishing a robust CUP pathway in academic and community centers across the US​.

View First Resource View Second Resource

Jazz Pharmaceuticals Study for Adults Suffering from HER2-positive Biliary Tract Cancer

Posted on 05/14/2025

Jazz Pharmaceuticals is sponsoring a clinical study evaluating the safety and efficacy of an investigational medicine called zanidatamab for the treatment of advanced HER2-positive biliary tract cancer. Visit Biliary Tract Cancer Study - Inform Herizon BTC-302 Study - Jazz Pharmaceuticals or click the resource below to learn more.

View Resource

This Is Living With Cancer™

Posted on 04/24/2025

This Is Living With Cancer™ is a free online resource developed by Pfizer Oncology for all people living with cancer, regardless of age, income, race, location, cancer type, or stage of disease. This comprehensive program is available to anyone in the United States, whether they're on a Pfizer treatment or not, with a growing focus on those facing challenges accessing care.

Direct your patients to ThisIsLivingWithCancer.com to learn more.

View Resource

Anemia in Focus: The Challenge of Identifying Myelodysplastic Syndromes (MDS)

Published on: February 17, 2025

Watch Dr. David Sallman, a leading MDS specialist at the Moffitt Cancer Center, talk about the importance of investigating unexplained anemia.

View Resource Here

Centers for Medicare & Medicaid Services has assigned a permanent J-code for RYTELO

Posted on 1/16/2025

Consider updating your billing software to reflect the permanent J-code for RYTELO, J0870, and units: 1 unit per 1 mg, so J-code can be used on or after January 1, 2025.
View Resource

Genentech-Pro: Product, Access, and Disease State Resources for Providers & Patients

Posted on 12/28/2024

View Resource

2025 Inflation Reduction Act (IRA) FRM

Posted on 11/13/2024

Changes to Medicare Part D in 2025 will Cap Out-Of-Pocket (OOP) Costs for Patients. Please feel free to review & share this important resource.
View Resource

ADC Cast is a Non-Promotional Educational Podcast Series Dedicated to Antibody Drug Conjugates (ADCs) in Breast Cancer

Posted on 10/16/2024

Hosted by Dr Javier Cortés and Prof. Peter Schmid, joined by an international panel of experts in ADCs and breast cancer, this educational podcast series unveils invaluable insights into ADCs, shedding light on their developmental history, their distinctive structural features and mechanisms of action, as well as potential future advancements.

Posted on 10/16/2024

Listen Here

Small Moments Can Help You Spot Endometrial Cancer

Posted on 08.12.2024

Too often, women with endometrial cancer (EC) have reported that their symptoms were stigmatized and dismissed. Even though diagnoses and deaths from this type of uterine cancer are on the rise, EC remains under-recognized.

Spot Her® is an initiative to help end the silence around EC and empower all people across generations and cultures to speak up, take action, and spot the potential signs at an early stage—when EC may be more treatable.
Learn More